Podcasts about future management

Ob Politik, Wirtschaft, Gesellschaft oder Technologie – selten zuvor waren die Umbrüche so tiefgreifend und rasant wie heute. Doch wie lassen sich die zentralen Kräfte hinter diesem Wandel erkennen? Und wie können wir sie gezielt für die Gestaltung unserer Zukunft nutzen? In dieser Folge des news aktuell Podcast begeben wir uns auf eine spannende Reise in die Zukunft. Dazu haben wir einen der führenden Zukunftsforscher im deutschsprachigen Raum eingeladen: Harry Gatterer, Geschäftsführer des Zukunftsinstituts. Mit ihm sprechen wir darüber, wie Zukunftsforschung funktioniert und welche Megatrends 2025 besonders dynamisch sind. Außerdem klärt er uns über die Kunst des Future Managements auf und darüber, welche Fragen sich Unternehmen heute stellen müssen, um morgen erfolgreich zu sein. Gliederung: Einleitung: ab Minute 00:00 Wie Harry Gatterer zum Zukunftsforscher wurde: ab Minute 02:16  Wie das Zukunftsinstitut arbeitet: ab Minute 04:54  Die Megatrend-Map: ab Minute 08:07  Die vier Dimensionen des Future Management: ab Minute 19:00  Erste Schritte bei der Implementierung von Future Management: ab Minute 22:59  Wie Unternehmen Future Management strategisch nutzen können / Spoiler news aktuell Academy Webinar mit Harry Gatterer: ab Minute 29:54  "Game-Changer" für Harry Gatterer: ab Minute 32:33  Schlussworte: ab Minute 37:41 Wer das Thema vertiefen will: Am 29. April 2025 zeigt Harry Gatterer in der news aktuell Academy, wie Future Management ganz konkret im Arbeitsalltag angewendet werden kann. Zur Anmeldung zum Webinar "Trends & Themen der Zukunft kennen, verstehen und antizipieren" Harry Gatterer auf LinkedIn Zukunftsinstitut im Web Homepage LinkedIn Instagram Facebook Megatrend-Map 2025 zum Download Am Host-Mikrofon: Beatrix Ta und Marissa Neureiter  Fragen, Anregungen oder Feedback? Schreibt uns: podcast@newsaktuell.de Hashtag für Social Media: #napodcast Vita Harry Gatterer Harry Gatterer ist Geschäftsführer des Zukunftsinstituts und ständig auf Entdeckungsreise: zu möglichen Zukünften, neuen Methoden und Strategien. Er verknüpft gesellschaftliche Trends mit unternehmerischen Entscheidungen und ist Experte darin, Potenziale zu identifizieren, ihre strategischen Impacts zu erkennen und sie zu nutzen. Zentrale Bestandteile seiner Arbeit sind die Vernetzung mit außergewöhnlichen Personen in führenden Zukunftsdisziplinen sowie das Sparring mit Top-Entscheidungsträgern aus der Wirtschaft. Sein erstes eigenes Unternehmen gründete Harry Gatterer im Alter von 20 Jahren, heute ist er Methodenentwickler, Berater, Autor und gefragter Interview-Partner. Als Keynote Speaker bringt er ein realistisches und zugleich kritisch-optimistisches Verständnis für Zukunft auf die Bühne. Er unterstützt dabei, wieder Vorstellungen und Bilder von Zukunft, den Mut für das aktive Gestalten und die Freude an Lösungen zu finden – kurzum: einen produktiven Umgang mit Zukunft.

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.

Featuring slide presentations and related discussion from Prof Martin Hutchings, Dr Manali Kamdar, Dr Matthew Lunning and Prof Gilles Salles, including the following topics: Evolving Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (0:00) Case: A 61-year-old man with Stage IV non-GCB DLBCL receives R-CHOP but experiences disease progression 8 months later (30:39) Case: A 68-year-old man with double-hit DLBCL who experiences disease progression on chemotherapy and second-line CAR T-cell therapy receives glofitamab (39:22) Incorporation of Bispecific Antibody Therapy into DLBCL Management — Prof Hutchings (45:25) Case: A 42-year-old man with progressive DLBCL refractory to 2 lines of therapy receives glofitamab with a durable response (1:07:30) Case: An 81-year-old woman with multiregimen-refractory DLBCL experiences a prolonged response to epcoritamab (1:14:25) Case: A 69-year-old man with follicular lymphoma transformed to DLBCL and refractory to 3 lines of treatment receives glofitamab (1:21:48) Selection and Sequencing of Other Available Therapies for Relapsed/Refractory (R/R) DLBCL — Prof Salles (1:24:37) Case: An 82-year-old woman with follicular lymphoma transformed to DLBCL receives tafasitamab/lenalidomide (1:42:05) Case: A 69-year-old man with urinary bladder carcinoma and recurrent GCB DLBCL receives loncastuximab tesirine (1:46:26) Promising Investigational Approaches for Patients with R/R DLBCL — Dr Lunning (2:00:37) Case: An 80-year-old woman with multiregimen-refractory GCB DLBCL seeks treatment requiring minimal clinic visits and receives loncastuximab tesirine (2:15:59) Case: A 54-year-old man with primary refractory non-GCB DLBCL receives CAR T-cell therapy, and follow-up imaging on day 29 demonstrates a Deauville score of 4 (2:25:22) CME information and select publications

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.

Dr Joyce O'Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices. CME information and select publications here.

Featuring slide presentations and related discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof Peter Schmid, including the following topics: Strategies to Identify Patients with HER2-Low and HER2-Ultralow Breast Cancer (0:00) Case: A woman in her mid 50s initially presenting with ER-positive, HER2 IHC 1+ locally advanced breast cancer who experiences progression to HER2 0 metastatic disease (20:53) Case: A woman in her early 60s with ER-positive, HER2 IHC 1+ metastatic breast cancer (mBC) who experiences disease progression 8 months after starting first-line CDK4/6 and aromatase inhibitor (29:14) Expanding the Spectrum of Targeted Therapy (38:52) Case: A woman in her early 60s with HR-positive, HER2 IHC 1+ mBC who receives fifth-line T-DXd resulting in stable disease (1:04:13) Case: A woman in her early 50s with progressive HR-positive, HER2 IHC 0 mBC and an ESR1 mutation who has ultralow HER2 expression on rebiopsy of new liver lesions (1:12:35) Identification and Management of Adverse Events with T-DXd (1:20:27) Case: A woman in her late 40s with HR-positive, HER2 IHC 2+ mBC who experienced persistent low-grade nausea with T-DXd that resolved with olanzapine (1:34:02) Case: A woman in her early 60s with ER-positive, HER2 2+ mBC who received T-DXd resulting in fatigue and asymptomatic interstitial lung disease (1:48:58) CME information and select publications  

Dr Joyce O'Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices. CME information and select publications here.

Zum Start ins neue Jahr wagt Thomas einen Blick in die Zukunft unserer Arbeitswelt – und das zusammen mit Pero Micic, Gründer und Vorstand der Future Management Group und Experte für Zukunftsstrategien. Gemeinsam diskutieren sie eine Frage, die uns alle bewegt: Wie sicher sind unsere Jobs in der Ära von KI?

Featuring perspectives from Dr Suresh S Ramalingam and Dr Gregory J Riely, including the following topics: Introduction: Tumor Treating Fields (0:00) Nontargeted Therapy for Lung Cancer — Dr Ramalingam (4:02) Targeted Therapy for Non-Small Cell Lung Cancer — Dr Riely (33:50) CME information and select publications

Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.

Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia, and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York, discuss the implications of recent data sets for the current and future management of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostESMO24/Lung).

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Philip A Philip, including the following topics: Introduction (0:00) Colorectal Cancer, Anal Cancer and Pancreatic Cancer — Dr Philip (1:56) Gastroesophageal Cancers, Hepatocellular Cancer and Biliary Tract Cancers — Dr Bekaii-Saab (41:48) CME information and select publications

Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers.

Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers.

Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers.

Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostESMO24/GI).

Featuring perspectives from Dr Jacob Sands, including the following topics: Introduction: A man in his mid 60s with a lung nodule on lung cancer screening (0:00) Current and Future Management of Small Cell Lung Cancer (15:42) CME information and select publications

Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.

Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/WCLC2024/SCLC).

Featuring perspectives from Dr Christopher Flowers, Prof Grzegorz S Nowakowski and Dr Laurie H Sehn, moderated by Dr Flowers, including the following topics: Introduction (0:00) Front-Line Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn (1:56) Case: A woman in her late 40s with epidural DLBCL and a compression fracture (Dr Flowers) (12:45) Case: A woman in her late teens with primary intestinal large B-cell lymphoma (Dr Nowakowski)(16:51) Integration of Novel Agents into the Care of Patients with Relapsed/Refractory DLBCL — Dr Flowers (21:14) Case: A man in his late 70s diagnosed with DLBCL with recurrent disease (Dr Nowakowski) (29:38) Case: A woman in her mid 70s with multiple comorbidities diagnosed with DLBCL (Dr Sehn) (36:17) Bispecific Antibody Therapy for DLBCL — Dr Nowakowski (39:39) Case: A man in his late 50s with no comorbidities with recurrent DLBCL (Dr Sehn) (50:50) Case: A patient in their mid 50s with DLBCL who experiences disease relapse after R-CHOP and CAR-T therapies (Dr Flowers) (54:34) CME information and select publications

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Corey J Langer, including the following topics: Introduction: A Model for Targeted Treatment in Non-Small Cell Lung Cancer (NSCLC) (0:00) NSCLC with ALK, ROS1 and NTRK Rearrangements — Dr Langer (9:10) Current and Future Treatment of Metastatic NSCLC with RET, MET, HER2 and KRAS Alterations — Dr Dagogo-Jack (34:22) CME information and select publications

Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/WCLC2024/TargetedLung).

Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.

Featuring perspectives from Dr Joshua K Sabari and Dr Helena Yu, including the following topics: Introduction: Checkpoint Inhibitors and Lung Cancer with an EGFR Mutation (0:00) Current Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations — Dr Sabari (5:39) Novel Therapeutic Approaches for NSCLC Harboring EGFR Mutations — Dr Yu (28:21) CME information and select publications

Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.

Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/WCLC2024/EGFRNSCLC).

Featuring slide presentations and related discussion from Dr Lipika Goyal, Dr James J Harding, Dr Milind Javle and Dr Robin K (Katie) Kelley, including the following topics: Current Role of Immunotherapeutic Strategies for Advanced Biliary Tract Cancers (BTCs) — Dr Kelley (0:00) Case: A man in his late 60s with advanced distal cholangiocarcinoma treated with the TOPAZ-1 regimen (13:27) Case: A woman in her early 70s with recurrent gallbladder cancer with biliary obstruction (15:56) Targeting FGFR and IDH Alterations for Advanced BTCs — Dr Goyal (35:00) Case: A woman in her late 30s with FGFR2 fusion-positive intrahepatic cholangiocarcinoma (ICC) (54:25) Case: A man in his late 60s with cholangiocarcinoma metastases to liver and bone (1:01:33) Case: A woman in her 60s with ICC with an IDH1 mutation (1:10:05) Emerging Role of HER2-Targeted Therapy for Advanced BTCs — Dr Harding (1:21:15) Case: A man in his early 40s with cholangiocarcinoma metastatic to the appendix (1:57:25) New Directions in the Management of BTCs — Dr Javle (2:01:09) CME information and select publications

Dr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/BTCThinkTank2024).

Dr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field.

Dr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field.

Dr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field.

Featuring slide presentations and related discussion from Dr Pasi A Jänne, Prof Tom John, Dr Zofia Piotrowska and Dr Alexander I Spira, including the following topics: Recent Advances in the Management of Localized and Locally Advanced Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Prof John (0:00) First-Line Treatment for Advanced NSCLC with an EGFR Mutation — Dr Spira  (32:48) Later-Line Therapy for Advanced NSCLC with an EGFR Mutation — Dr Jänne (1:03:51) Management of NSCLC with an EGFR Exon 20 Mutation — Dr Piotrowska (1:33:33) CME information and select publications

Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.

Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation. CME information and select publications here (https://www.researchtopractice.com/EGFRNSCLCThinkTank2024)

Featuring an interview with Dr Jonathan W Goldman, including the following topics: Contemporary and Future Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:00) Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation (21:05) Other Emerging Strategies for Relapsed Metastatic Lung Cancer (29:16) Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation (37:59) Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation (45:29) CME information and select publications

Featuring perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics: Introduction (0:00) Contemporary Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Langer (2:08) Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation — Dr Goldman (22:37) Biological Rationale for and Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation — Dr Yu (43:23) Other Emerging Strategies for Relapsed Metastatic NSCLC with an EGFR Mutation — Dr Sabari (1:03:33) Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation — Dr Piotrowska (1:20:15) Management of Toxicities Associated with Available and Emerging Therapies for NSCLC with an EGFR Mutation — Dr Neal (1:38:44) CME information and select publications

Episode 158 Sam James Velde of Future Management and much more According to my brother Mexi Mike, Sam Velde may be the Forrest Gump of the Hardcore scene. He happened to be at many great moments throughout the last 4 decades. He also takes all that he has gleaned and put it into his current focus as a manager for Scowl and partner with Ricky Singh of Future Management. His journey is a great one and a fun story he got to retell. www.instagram.com/samjamesvelde Opening Track Of The Episode Trail Of Life "Only The Strong"

Featuring perspectives from Ms Marianne J Davies, Dr Alexander I Spira, Ms Jillian Thompson and Dr Helena Yu, including the following topics: Introduction (0:00) The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) (7:02) The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation (11:58) Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (32:38) Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (37:45) Common Toxicities Associated with Amivantamab (45:07) The Current and Future Management of Progressive NSCLC with an EGFR Mutation (55:06) Tolerability and Other Practical Considerations with HER3-DXd (1:01:06) Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations (1:18:26) CME information and select publications

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

Featuring perspectives from Prof Nicoletta Colombo, Dr Matthew A Powell and Dr Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics: Introduction (0:00) Current Approaches to First-Line Therapy for Advanced Endometrial Cancer (EC) — Prof Colombo (1:57) Novel Investigational Strategies for Newly Diagnosed EC — Dr Westin (25:35) Current Options for Relapsed/Refractory EC — Dr Slomovitz (45:57) Role of HER2-Targeted Therapy in the Management of Advanced EC — Dr Powell (1:05:54) CME information and select publications

Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics: Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00) Biology and Current Clinical Management of PNH (36:35) Future Directions in PNH Management (55:34) Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26) CME information and select publications

Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PNHThinkTank2024).

Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease.

Featuring perspectives from Dr Joyce F Liu, Dr Mansoor Raza Mirza and Dr David M O'Malley, moderated by Dr Kathleen N Moore, including the following topics: Introduction (0:00) Current Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu (2:06) Potential Role of Immunotherapeutic Strategies for Advanced OC — Dr O'Malley (25:12) Incorporation of Novel Therapies into the Management of Relapsed/Refractory OC — Dr Moore (48:23) Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Mirza (1:06:59) CME information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Dr Elisabeth I Heath and Dr A Oliver Sartor, moderated by Dr Alan H Bryce, including the following topics: Introduction (0:00) Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Aggarwal (1:51) Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer — Dr Antonarakis (25:39) New Considerations with PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Bryce (47:31) Role of Novel Radiopharmaceuticals in Therapy for mCRPC — Dr Sartor (1:10:09) Promising Investigational Approaches for Patients with Prostate Cancer — Dr Heath (1:32:05) CME information and select publications  

Featuring perspectives from Dr Matthew Milowsky, Dr Peter H O'Donnell, Dr Jonathan E Rosenberg and Dr Arlene Siefker-Radtke, moderated by Dr Evan Y Yu, including the following topics: Introduction (0:00) Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Milowsky (2:54) Other Novel Strategies Under Investigation for Nonmetastatic UBC — Dr O'Donnell (25:53) Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg (49:43) Emerging Role of HER2-Targeted Therapy for mUBC — Dr Yu (1:12:03) Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke (1:35:51) CME information and select publications    

Featuring perspectives from Dr David H Ilson, Dr Rutika Mehta, Dr Markus Moehler and Dr Manish A Shah, moderated by Dr Harry H Yoon, including the following topics: Introduction (0:00) Recent Developments in the Management of Localized or Locally Advanced Gastroesophageal Cancers — Dr Ilson (2:02) Incorporation of First-Line Immunotherapeutic Strategies for Patients with Metastatic Gastroesophageal Tumors — Dr Yoon (26:40) Emerging Role of Therapy Targeting Claudin 18.2 in Advanced Gastric/GEJ Adenocarcinoma — Dr Shah (50:10) Current Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers — Dr Moehler (1:13:14) Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) HER2-Negative Gastroesophageal Cancers — Dr Mehta (1:34:54) CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr Stephen M Ansell, Dr Nancy L Bartlett, Dr Jonathon B Cohen, Dr Jonathan W Friedberg and Dr Brad S Kahl, including the following topics: Introduction (0:00) Evolving Role of Novel Treatment Strategies in Follicular Lymphoma (FL) — Dr Friedberg (7:20) Integration of CAR (Chimeric Antigen Receptor) T-Cell Therapies and Bispecific Antibodies into the Management of FL — Dr Abramson (33:08) Up-Front Treatment for Mantle Cell Lymphoma (MCL) — Dr Kahl (58:54) Therapeutic Sequencing for Patients with Relapsed/Refractory (R/R) MCL — Dr Cohen (1:23:46) First-Line Treatment Strategies for Hodgkin Lymphoma (HL) — Dr Bartlett (1:45:42) Current and Future Management of R/R HL — Dr Ansell (2:18:49) CME information and select publications

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer | Faculty Presentation 2: Targeted Therapy for Metastatic NSCLC — Zofia Piotrowska, MD, MHS  CME information and select publications

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer | Faculty Presentation 3: Immunotherapeutic and Other Novel Strategies for Metastatic NSCLC and Small Cell Lung Cancer — Aaron Lisberg, MD   CME information and select publications